Open Access
MATEC Web of Conferences
Volume 22, 2015
International Conference on Engineering Technology and Application (ICETA 2015)
Article Number 05001
Number of page(s) 10
Section Chemical and Industrial Technology
Published online 09 July 2015
  1. Pauson P L. 1954. Ferrocene Derivatives. Part I. The direct synthesis of substituted ferrocenes. J. Am. Chem. Soc. 76(8): 2187–2191. [CrossRef]
  2. Kealy T J. & Pauson P L. 1951. A new type of organo-iron compound. Nature. 168: 1039. [CrossRef]
  3. Yuan.Y.F. & Ye.S.M. 1995. Ferrocene derivatives with biological (Richard) activity .Chemistry; 5: 24–31.
  4. Babin VN, Dubinin AV, Raevskii PM, Sviridov AF. & Sherman AL. 1979. Model’ khimicheskogo carcinogeneza (molekulyarnye aspekty). Modeli. Algoritmy. Prinyatie Reshenii. Nauka: Moscow, 153–167.
  5. Popova (Snegur) LV, Babin VN, Belousov YuA, Nekrasov YuS, Snegireva AE, Borodina NP, Shaposhnikova GM, Bychenko OB, Raevskii PM, Morozova NM, Ilyina AI,Shitkov KG. 1993. Antitumor effects of binuclear ferrocene derivatives. Appl. Organometal. Chem. 7: 85. [CrossRef]
  6. Kopf-Maier P, Kopf H. & Neuse EW. 1984. Ferrocenium Salts—The First Antineoplastic Iron Compounds. Angew. Chem. 96: 446. [CrossRef]
  7. Lubov V. Snegur, Yury S. Nekrasov, Nataliya S. Sergeeva, Zhanna V. Zhilina, Vera V Gumenyuk, Zoya A. Starikova, Alexander A. Simenel, Nataliya B. Morozova, Irina K. Sviridova & Valery N. Babin. 2008. Ferrocenylalkyl azoles: Bioactivity, synthesis, structure. Appl. Organometal. Chem. 22: 139–147. [CrossRef]
  8. Amir, E.; Freedman, O. C.; Seruga, B. & Evans, D. G. 2010. Assessing women at high risk of breast cancer: a review of risk assessment models. J. Natl. Cancer Inst. 102: 680–691. [CrossRef]
  9. Grodin, J. M.; Siiteri, P. K. & MacDonald, P. C. 1973. Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab. 36: 207–214. [CrossRef]
  10. O’Neill, J. S.; Elton, R. A. & Miller, W. R. 1988. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br. Med. J (Clin. Res. Ed.). 296: 741–743. [CrossRef]
  11. Brueggemeier, R. W. 2006. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 7: 1919–1930. [CrossRef]
  12. Brueggemeier, R. W; Hackett, J. C. & Diaz-Cruz, E. S. 2005. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26: 331−345. [CrossRef]
  13. Debashis Ghosh, Jessica Lo, Daniel Morton, Damien Valette, Jingle Xi, Jennifer Griswold, Susan Hubbell, Chinaza Egbuta, Wenhua Jiang, Jing An, & Huw M. L. Davies. 2012. Novel aromatase inhibitors by structure-guided design. J. Med. Chem. 55: 8464–8476. [CrossRef]
  14. Ghosh, D.; Griswold, J.; Erman, M. & Pangborn, W. 2009. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 457, 219−223. [CrossRef]
  15. Gong X, Yang X. & Wang D X. 2006. A new route for the synthesis of N-substituted diketopiperazine derivatives. Chin. Chem. Lett. 17(4): 469–472.
  16. Xiao Q, Jiu Feng Z, Hong Li Z. & Min Bo L. 2009. Synthesis and mechanism research of two kinds of ferrocene carboxylic acid based on Willgerodt-Kindler reaction. Chin. Organic. Chemistry. 29(5): 748–752.
  17. Kenneth L, Rinehart J R, Cursu, J R. & Phillip E S. 1957. Organic chemistry of ferrocene. II. the preparation of ferrocenyl aliphatic. J. Am. Chem. Soc. 79(13): 3420–3424. [CrossRef]